Elevated HbA2 Generally Confirms β-Thalassemia Carrier Status Without DNA Analysis
For typical β-thalassemia carrier screening, DNA analysis is not required when HbA2 is clearly elevated (≥3.6-4.0%), as this is the most decisive test for β-carrier detection 1, 2. However, this straightforward approach has important exceptions that require molecular confirmation.
When DNA Analysis is NOT Needed
An elevated HbA2 level (typically ≥3.6-4.0%) in the context of:
- Microcytic hypochromic red cells (MCV 60-70 fL, MCH 19-23 pg)
- Normal or mildly reduced hemoglobin
- Excluded iron deficiency (normal ferritin/zinc protoporphyrin)
- No hemoglobin variants on HPLC
This combination reliably identifies β-thalassemia carriers without molecular testing 1, 2.
Critical Situations Requiring DNA Analysis Despite Elevated HbA2
1. Borderline HbA2 Values (3.6-4.0%)
Recent evidence shows that at borderline HbA2 levels, there is a higher proportion of normal β-globin genes, diagnostic errors, and misinterpretations 3. In Thailand, when the cutoff changed from 4.0% to 3.6%, only 94.8% of subjects with HbA2 ≥3.6% actually carried β-thalassemia mutations, with 3.5% having normal genes 3.
2. Elevated HbF with Normal HbA2
This is a major diagnostic pitfall. Compound mutations involving δ-globin and γ-globin genes can normalize HbA2 levels even in true β-thalassemia carriers 4. Patients presenting with microcytosis, elevated HbF (≥5.0%), but normal HbA2 require comprehensive genetic testing of β-, δ-, and γ-globin genes to avoid missed diagnosis 4.
3. Hemoglobin Variants Present
When HPLC shows abnormal peaks, DNA analysis becomes essential. Certain variants (Hbs Hope, Tak, Cook, C, Lepore, Q-Thailand) can co-migrate with HbA2 or HbF, creating falsely elevated readings 5. The misinterpretation rate reaches 71.9% when both HbA2 ≥3.6% and HbF ≥5.0% are present with variants 5.
4. Poorly Controlled Diabetes
Elevated HbA1c (110-180 mmol/mol) significantly reduces measured HbA2 levels (2.0% vs 2.4% in controls), potentially masking β-thalassemia carriers 6. In diabetic patients with microcytosis but "normal" HbA2, DNA testing is warranted.
5. α-Thalassemia Confirmation
Unlike β-thalassemia, molecular analysis is necessary to confirm α-thalassemia carrier status 1. α-carriers show only slight MCV/MCH reduction and may have lower-than-normal HbA2, making DNA analysis essential for definitive diagnosis.
6. Prenatal Diagnosis and Family Planning
When both partners are carriers, molecular diagnosis is essential to:
- Predict disease severity (transfusion-dependent vs. intermediate forms)
- Enable prenatal diagnosis on chorionic villi
- Determine specific mutations for accurate genetic counseling 1
Practical Algorithm
Step 1: Check MCV, MCH, and exclude iron deficiency (ferritin, TSAT)
Step 2: Perform HPLC for HbA2 and HbF quantification
Step 3: Decision point:
- HbA2 clearly elevated (>4.0%) + no variants + no diabetes → Diagnose β-thalassemia carrier, no DNA needed
- HbA2 borderline (3.6-4.0%) → Consider DNA analysis for confirmation
- HbA2 normal but elevated HbF + microcytosis → DNA analysis mandatory (test β-, δ-, γ-globin genes)
- Hemoglobin variants present → DNA analysis mandatory
- Poorly controlled diabetes (HbA1c >110 mmol/mol) → DNA analysis if microcytic
- α-thalassemia suspected → DNA analysis mandatory
Common Pitfalls to Avoid
- Assuming all elevated HbA2 is β-thalassemia - Hemoglobin variants can falsely elevate readings 5
- Missing compound mutations - Normal HbA2 with elevated HbF can mask β-thalassemia 4
- Ignoring diabetes status - HbA1c glycation reduces measured HbA2 6
- Using single HPLC method - Combining two different methods improves accuracy when variants suspected 5
- Not testing α-thalassemia molecularly - Clinical diagnosis alone is insufficient 1
The key principle: elevated HbA2 is highly reliable for β-thalassemia carrier diagnosis in straightforward cases, but multiple modifying factors can create false-positive or false-negative results requiring molecular confirmation.